ABOUT US

MedAccess Board and Governance

Led by Nigel Keen, our Chair, the MedAccess board is responsible for our oversight and governance. Board members are drawn from the fields of public health, pharmaceuticals and finance.

Meet the MedAccess Board

Nigel Keen

Board Chair
Nigel brings decades of experience in healthcare and commerce to the governance of MedAccess, having been involved in the formation of high technology businesses for more than 30 years.

Nigel is a member of the Project Investment Committee and he Chairs the Remuneration & Nominations Committee.
Nigel Keen

Nigel Keen

Board Chair

Nigel brings decades of experience in healthcare and commerce to the oversight and governance of MedAccess. His career has encompassed venture capital, industry and banking, and he has been involved in the formation and development of high technology businesses for more than 30 years.

He is currently Chairman of Syncona Investment Management, Oxford Academic Health Science Network and Oxford University Innovation. He also Chairs the AIM-listed medical device company Deltex Medical Group.

Daniel Camus

Board Member
Daniel brings 25 years’ experience in international finance to his position as a MedAccess director, and joined the MedAccess Board in 2020 from his role as CFO of the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Daniel is the Chair of the Audit & Compliance Committee.
Daniel Camus

Daniel Camus

Board Member

Daniel brings 25 years’ experience in international finance to his position as a MedAccess director. During 11 years with the pharmaceutical group Aventis, he held a number of Chief Financial Officer roles, followed by 10 years as CFO at energy firm EDF. Daniel most recently served as CFO of the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Daniel holds several other Non-Executive Director positions including with the Foundation for Innovative New Diagnostics (FIND), a Swiss-based non-profit healthcare organisation.

Diana Noble CBE

Board Member
Diana brings more than 30 years of experience in private equity, venture capital and international development. She combines Board responsibilities with chairing the MedAccess Investment Committee.

Diana is the Chair of the Project Investment Committee.
Diana Noble CBE

Diana Noble CBE

Board Member

Diana brings over 30 years’ experience in private equity, venture capital and international development. She combines Board responsibilities with chairing the MedAccess Investment Committee.

Diana has held roles of CEO at CDC Group, Executive Vice President Operations at the Clinton Health Access Initiative and Partner at Schroder Ventures (now Permira).

Dr. Egbe Osifo-Dawodu

Board Member
Egbe is a Partner at the Anadach Group, and a member of the UK Royal College of Physicians. Egbe’s 30 years of healthcare experience covers policy, provision and financing in Africa, Asia, Europe, and Latin America.

Egbe is a member of the Audit & Compliance Committee.
Dr. Egbe Osifo-Dawodu

Dr. Egbe Osifo-Dawodu

Board Member

Egbe is a Partner at the Anadach Group, providing advisory services to a wide range of clients. She is a member of the UK Royal College of Physicians, with over 30 years’ healthcare experience covering policy, provision and financing in Africa, Asia, Europe, and Latin America.

Egbe has held various positions at the World Bank Group, working on public policy and investment transactions at the International Financial Corporation.

Holger Rothenbusch

Board Member
Holger is Managing Director of the Debt Team at CDC Group. Holger has spent 20 years in development finance in Latin America, Africa, Asia and Eastern Europe, working across emerging markets, sectors and products.

Holger is a member of the Project Investment Committee and the Remuneration & Nominations Committee.
Holger Rothenbusch

Holger Rothenbusch

Board Member

Holger is Managing Director of the Debt team at CDC Group. He has spent over 20 years in development finance in Latin America, Africa, Asia and Eastern Europe, working across numerous emerging markets, sectors and products.

Prior to joining CDC, Holger held several senior positions at the German Development Finance Institution, including building the Equity & Mezzanine Team. He started his career as a commercial banker with Deutsche Bank.

Willem Verhoofstad

Board Member
Willem has three decades’ experience in the pharmaceutical industry, holding leadership roles in product development, business development, strategic marketing, R&D strategy and portfolio management.

Willem is a member of the Audit & Compliance Committee and the Remuneration & Nominations Committee.
Willem Verhoofstad

Willem Verhoofstad

Board Member

Willem is a former Senior Vice President at Roche Pharma in Switzerland.

He has over 34 years of experience in the pharmaceutical industry, culminating in various global leadership roles in product development, business development, strategic marketing, R&D strategy and portfolio management. His broad and deep experience covers a wide range of therapeutic areas and geographies.

Governance

The MedAccess Board and its committees are actively involved in the oversight of our organisation. Board members and committee members take a close interest in our success, providing guidance, scrutiny and approval on key activities.

The Board meets a minimum of four times per year to review MedAccess’ progress against its business plan targets and provide strategic input and guidance to the executive team.

Board Committees

The Board delegates specific tasks and decisions to three standing committees, which have Committee Chairs that report on their activities to the Board:

  • The Project Investment Committee screens and evaluates potential transactions and can provide approval on proposals up to $75 million. Membership of the Committee includes John Kelting, an independent member.
  • The Audit and Finance Committee provides oversight on MedAccess financial activities. Made up of a minimum of three members, this Committee reviews the organisation’s financial statements and provides guidance on risk and compliance.
  • The Remuneration & Nominations Committee is responsible for approving and monitoring all aspects of remuneration and performance.